L002 (NSC764414) is primarily investigated for its potential in cancer research due to its ability to inhibit specific enzymes involved in tumor growth and progression. It has shown promise in targeting pathways that regulate cell proliferation and survival, making it a candidate for further studies in oncology. Additionally, L002 is explored for its role in epigenetic modulation, particularly in inhibiting histone-modifying enzymes, which could influence gene expression patterns associated with diseases. Its application extends to understanding molecular mechanisms in various cellular processes, aiding in the development of novel therapeutic strategies.